Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future
Raffaele Costanzo1, Agnese Montanino, Massimo Di Maio
1Thoraco-Pulmonary Department, Medical Oncology Unit, Istituto Nazionale Tumori "Fondazione G.Pascale" - IRCCS Napoli, Italy.
Abstract:
The identification of activating mutations in the tyrosine kinase domain of the EGF receptor (EGFR) predictive of response to tyrosine kinase inhibitors (TKIs) led to a therapeutic revolution in the treatment of patients with metastatic non-small-cell lung cancer (NSCLC). To date, eight randomized clinical trials have demonstrated that first-line treatment with TKIs in advanced NSCLC patients harboring activating EGFR mutations is associated with significant improvement in response rate, progression-free survival, quality of life and tolerability, compared with platinum-based chemotherapy. These results prompted the EGFR TKIs as the current standard first-line treatment of patients with advanced NSCLC harboring activating EGFR mutations. However, there are several questions that need to be addressed, including the best choice among different EGFR TKIs, the treatment of resistant disease and of patients with specific clinical conditions. Ongoing and future, well-designed trials should answer all these questions.
Insights
Activating mutations in the Epidermal Growth Factor Receptor (EGFR) guide targeted therapy for non-small-cell lung cancer (NSCLC). EGFR tyrosine kinase inhibitors (TKIs) are now standard first-line treatment, improving outcomes for patients with advanced NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Activating mutations in the Epidermal Growth Factor Receptor (EGFR) tyrosine kinase domain predict response to tyrosine kinase inhibitors (TKIs).
- This discovery revolutionized the treatment of metastatic non-small-cell lung cancer (NSCLC).
Purpose of the Study:
- To review the established efficacy of EGFR TKIs in first-line treatment for advanced NSCLC patients with activating EGFR mutations.
- To identify remaining questions regarding optimal TKI selection, resistance, and specific patient populations.
Main Methods:
- Systematic review of eight randomized clinical trials comparing first-line EGFR TKIs with platinum-based chemotherapy.
- Analysis of outcomes including response rate, progression-free survival, quality of life, and tolerability.
Main Results:
- First-line EGFR TKIs significantly improve response rate, progression-free survival, quality of life, and tolerability compared to chemotherapy.
- EGFR TKIs are established as the standard first-line treatment for advanced NSCLC with activating EGFR mutations.
Conclusions:
- EGFR TKIs represent a major therapeutic advance for a specific subset of NSCLC patients.
- Further research is needed to optimize TKI choice, manage resistance, and address unique clinical scenarios.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...